Dr. Alpaslan Dedeoglu received his MD from the Istanbul University School of Medicine and completed a pharmacology program at the Marmara University in 1992. During and after his pharmacology program he worked at the University of Arizona, Ohio State University, and Massachusetts General Hospital; he then joined Boston University in 2000. Dr. Dedeoglu’s major research interests are neuroanatomy, neuropathology, and the neurochemistry of animal models of neurodegenerative disorders. His labs are located at the Boston VA Medical Center. Dr. Dedeoglu is the PI of several ongoing projects that are funded by the NIH, VA, and private foundations. He also works with therapeutic trials in rodent models of neurodegenerative disorders.
- VA Boston Healthcare System
- Istanbul University, MD
- Marmara University, PhD
- Published on 3/12/2018
Carreras I, Aytan N, Mellott T, Choi JK, Lehar M, Crabtree L, Leite-Morris K, Jenkins BG, Blusztajn JK, Dedeoglu A. Corrigendum to "Anxiety, neuroinflammation, cholinergic and GABAergic abnormalities are early markers of Gulf War illness in a mouse model of the disease" [Brain Res. 1681 (2018) 34-43]. Brain Res. 2018 Jun 01; 1688:113-115. PMID: 29526415.
- Published on 3/3/2018
Aytan N, Choi JK, Carreras I, Crabtree L, Nguyen B, Lehar M, Blusztajn JK, Jenkins BG, Dedeoglu A. Protective effects of 7,8-dihydroxyflavone on neuropathological and neurochemical changes in a mouse model of Alzheimer's disease. Eur J Pharmacol. 2018 Jun 05; 828:9-17. PMID: 29510124.
- Published on 12/24/2017
Carreras I, Aytan N, Mellott T, Choi JK, Lehar M, Crabtree L, Leite-Morris K, Jenkins BG, Blusztajn JK, Dedeoglu A. Anxiety, neuroinflammation, cholinergic and GABAergic abnormalities are early markers of Gulf War illness in a mouse model of the disease. Brain Res. 2018 02 15; 1681:34-43. PMID: 29277710.
- Published on 11/7/2017
Kantarci A, Aytan N, Palaska I, Stephens D, Crabtree L, Benincasa C, Jenkins BG, Carreras I, Dedeoglu A. Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease. Exp Neurol. 2018 Feb; 300:111-120. PMID: 29126887.
- Published on 4/27/2016
Aytan N, Choi JK, Carreras I, Brinkmann V, Kowall NW, Jenkins BG, Dedeoglu A. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. Sci Rep. 2016 04 27; 6:24939. PMID: 27117087.
- Published on 11/12/2015
Jenkins BG, Zhu A, Poutiainen P, Choi JK, Kil KE, Zhang Z, Kuruppu D, Aytan N, Dedeoglu A, Brownell AL. Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration. Neuropharmacology. 2016 Sep; 108:462-73. PMID: 26581500.
- Published on 10/6/2014
Choi JK, Carreras I, Aytan N, Jenkins-Sahlin E, Dedeoglu A, Jenkins BG. The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging. Brain Res. 2014 Nov 24; 1590:85-96. PMID: 25301691.
- Published on 3/15/2014
Korkmaz OT, Aytan N, Carreras I, Choi JK, Kowall NW, Jenkins BG, Dedeoglu A. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2014 Apr 30; 566:286-91. PMID: 24637017.
- Published on 3/11/2014
Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur JY, Zheng H, Li H, Fine R, Mwamburi M, Sun X, Kowall N, Stern RA, Qiu WQ. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. Mol Psychiatry. 2015 Feb; 20(2):252-62. PMID: 24614496.
- Published on 10/22/2013
Carreras I, McKee AC, Choi JK, Aytan N, Kowall NW, Jenkins BG, Dedeoglu A. R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease. Brain Res. 2013 Dec 6; 1541:115-27. PMID: 24161403.
View 37 more publications: View full profile at BUMC